{ "items": [ "\n\n
\n \n 1 April 2016\n \n
\n\n \n \n \n\n \n \n \nProf Helen McShane and her team at the Jenner Institute, have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.\r\n\r\nThe researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Gu\u00e9rin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
\n \n\n\n \n 1 April 2016\n \n
\n\n \n \n \n\n \n \n \nAlthough the Zika virus and other public health threats might seem more pressing, the world cannot ease up on efforts to maximize development of Ebola vaccines and prepare for the next outbreak, according to an expert panel in a report published today, \"Plotting the Course of Ebola Vaccines\". The report is produced by a team which was assembled in November 2014 by the Wellcome Trust and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota as the Ebola outbreak heated up in West Africa.
\n \n\n\n \n 23 March 2016\n \n
\n\n \n \n \n\n \n \n \nThree University of Oxford teams are to begin research projects focussed on Zika after the UK government announced a series of grants to tackle the disease. Since its outbreak in Brazil last year, the Zika virus has continued to spread, primarily across the Americas. Dr George Warimwe, Jenner Institute, will study the transmission and case burden of Zika in an area of East Africa, providing vital information on how the disease spreads.
\n \n\n\n \n 18 March 2016\n \n
\n\n \n \n \n\n \n \n \nOn 14 March, Mr Darren Nash, Associate Head of Department (Academic Support & Finance), Professor Arturo Reyes-Sandoval, Dr Cesar L\u00f3pez-Camacho and Dr Gilberto Estrada Harris welcomed a distinguished group of guests from the British Embassy in Mexico coming with a delegation of Mexican journalists from different media outlets on a tour exploring UK\u2019s science, technology and innovation, education, business and sustainability.
\n \n\n\n \n 11 March 2016\n \n
\n\n \n \n \n\n \n \n \nA podcast is now available of this year's Oxford London Lecture, a lecture series which aims to connect the widest possible audience to some of Oxford's ground-breaking research. The lecture was given by Director of the Jenner Institute, Prof Adrian Hill, on the topic \"Vaccines for Ebola: tackling a market failure\", followed by a panel discussion chaired by The Times columnist, Alice Thompson.
\n \n\n\n \n 10 March 2016\n \n
\n\n \n \n \n\n \n \n \nProfessor Adrian Hill, Director of the Jenner Institute, warns that more than a dozen viruses pose the threat of severe outbreaks, but there are currently no vaccines to protect against them.
\n \n\n\n \n 8 March 2016\n \n
\n\n \n \n \n\n \n \n \n8th March is International Women\u2019s Day, celebrating the social, economic, cultural and political achievement of women. To mark the day, Charvy Narain spoke to a woman with a significant record of scientific achievement: Professor Helen McShane. Professor McShane is a Wellcome Trust Senior Clinical Research Fellow at the Jenner Institute, and she was recently appointed the interim Deputy Head of the Nuffield Department of Medicine, the single largest department at the University of Oxford.
\n \n\n\n \n 1 March 2016\n \n
\n\n \n \n \n\n \n \n \nOxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.\r\n\r\nDr Irina Redchenko, a senior investigator on the trial from the Jenner Institute explained: \u2018Cancers can spread in the body is because the immune system does not recognise the cancer cells as foreign and so does not attack them. The right type of vaccine could help the body to attack and destroy the cancer cells.\u2019
\n \n\n\n \n 26 February 2016\n \n
\n\n \n \n \n\n \n \n \nTuesday 1st March 2016, 17:30 \u2013 18:30 \r\n\r\nOxford Sciences Innovation plc is a \u00a3320m partnership between the University of Oxford and Isis Innovation to find the most ground-breaking ideas coming out of Oxford and develop them into market-leading companies.\r\n\r\n Presentations and discussion on innovation and medicine in Oxford.\r\n Presentations by Oxford Sciences Innovation, life science academics and Oxford academic entrepreneurs, including Adrian Hill, Director of the Jenner Institute.\r\n\r\nAudience: Oxford researchers and DPhil students\r\n\r\nVenue: Lecture Auditorium, Christ Church, St Aldates, Oxford OX1 1DP\r\n\r\nCanapes and drinks from 18:30 onwards at The House Cocktail Bar, Wheatsheaf Yard, 11 Blue Boar St, Oxford OX1 4EE.\r\n\r\nTo secure your place, please email jleonard-love@oxfordsciences.com.\r\n\r\nTo read more: http://www.oxfordsciencesinnovation.com/\r\n\r\nhttp://isis-innovation.com/news/launch-of-300m-partnership-to-boost-development-of-science-and-technology-businesses/
\n \n\n\n \n 25 February 2016\n \n
\n\n \n \n \n\n \n \n \nApplications are now open for a new MRC 'Confidence in Concept' fund, managed by The Tropical Infectious Disease Consortium. The fund of \u00a3500,000 is aimed at projects that translate scientific discoveries into therapeutics, diagnostics and vaccine development.\r\n\r\nThe partners of the Consortium are London School of Hygiene and Tropical Medicine, Liverpool School of Medicine, The Jenner Institute at the University of Oxford, and Public Health England Microbiology Research Services, who will provide awards of up to \u00a350,000 via an open, competitive and peer-reviewed process (deadline 30th April 2016).
\n \n\n\n \n 17 February 2016\n \n
\n\n \n \n \n\n \n \n \nA research team led by a Kenyan scientist has produced the first Rift Valley Fever (RVF) vaccine that can be used by both humans and animals. In a study published this week in Scientific Reports, an online journal, the researchers demonstrated that a single injection with this vaccine is safe and offers complete protection against RVF in livestock and recommends that the vaccine be tried in humans.
\n \n\n\n \n 12 February 2016\n \n
\n\n \n \n \n\n \n \n \nA ten year retrospective has now been published online, including an overview of the Grand Challenge project Enhancing the efficacy and immunogeniciy of vectored vaccines headed by Adrian Hill.
\n \n\n\n \n 8 February 2016\n \n
\n\n \n \n \n\n \n \n \nOutbreak: Lessons from Ebola. On 6 December 2013 a two-year-old boy called Emile Ouamouno died of a serious illness in a small village in Guinea. A month later Emile\u2019s three-year-old sister, his mother and grandmother were all dead. This was the start of an Ebola epidemic that swept through West Africa in 2014, killing over 11,000 people and infecting nearly 30,000.
\n \n\n\n \n 21 January 2016\n \n
\n\n \n \n \n\n \n \n \nAn interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
\n \n\n\n \n 13 November 2015\n \n
\n\n \n \n \n\n \n \n \nApplications are now open for the prestigious Wellcome Trust funded 4 year PhD programme in Infection, Immunology and Translational Medicine.
\n \n\n\n \n 13 November 2015\n \n
\n\n \n \n \n\n \n \n \nProfessor Tomas Hanke is part of the European Aids Initiative project that brings together HIV researchers form across the world to develop protective and therapeutic HIV vaccines.
\n \n\n\n \n 13 November 2015\n \n
\n\n \n \n \n\n \n \n \nThe Jenner Institute has started phase I clinical trials testing a vaccine that tries to inhibit the growth of eggs in malaria mosquitoes, thus preventing malaria transmission from one person to another.
\n \n\n\n \n 29 July 2015\n \n
\n\n \n \n \n\n \n \n \nJust published - the report covers a summary of progress across the Institute's portfolio of research programmes and update on latest activities. \r\n\r\nThe Institute has expanded substantially in the last 10 years with several enlarging groups, strategic recruitments and a broadening base of funders from four continents. Recently, the Institute\u2019s capacity to undertake small scale first-in-human trials very rapidly was illustrated by the request from the World Health Organization to undertake, with collaborators, the first trial of a new Ebola vaccine destined for West Africa in the 2014 outbreak.
\n \n\n\n \n 14 July 2015\n \n
\n\n \n \n \n\n \n \n \nA clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University. The first volunteers of the trial at Centre Hospitalier Universitaire le Dantec in Dakar received an initial vaccination at the start of July, with a booster vaccination one week later. While this is a short timescale for immunisation, if proved successful it would provide an option to respond to an Ebola outbreak with a rapid vaccination programme.
\n \n\n\n \n 17 June 2015\n \n
\n\n \n \n \n\n \n \n \nLONDON, June 15 (Reuters) - Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers say there is no excuse for not having a vaccine that could have protected those now falling sick and dying in South Korea. \"The question is: How long are we going to wait around and just follow these outbreaks before we get serious about making vaccines?\" said Adrian Hill, a professor and director at the Jenner Institute at Britain's Oxford University.
\n \n\n